Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific...
Reexamination Certificate
2005-06-08
2010-11-23
Le, Emily M. (Department: 1648)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Reexamination Certificate
active
07838017
ABSTRACT:
The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with an antigen (e.g., as in a vaccine). The adjuvant compositions of the invention have particular physical properties (e.g., molecular weight, concentration, and pH) which address the need for a safe adjuvant for eliciting an enhanced immune response. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response to an antigenic compound.
REFERENCES:
patent: 3666646 (1972-05-01), Lampson et al.
patent: 3692899 (1972-09-01), Levy
patent: 3906092 (1975-09-01), Hilleman et al.
patent: 3952097 (1976-04-01), Levy
patent: 4024241 (1977-05-01), Levy
patent: 4082735 (1978-04-01), Jones et al.
patent: 4082736 (1978-04-01), Jones et al.
patent: 4094971 (1978-06-01), Chedid et al.
patent: 4101536 (1978-07-01), Yamamura et al.
patent: 4124702 (1978-11-01), Lampson et al.
patent: 4140761 (1979-02-01), Gerin et al.
patent: 4153684 (1979-05-01), Audibert et al.
patent: 4185089 (1980-01-01), Derrien et al.
patent: 4186194 (1980-01-01), Adam et al.
patent: 4235771 (1980-11-01), Adam et al.
patent: 4314998 (1982-02-01), Yamamura et al.
patent: 4323559 (1982-04-01), Audibert et al.
patent: 4327085 (1982-04-01), Audibert et al.
patent: 4349538 (1982-09-01), Levy
patent: 4369178 (1983-01-01), Yamamura et al.
patent: 4389395 (1983-06-01), Lerner et al.
patent: 4954298 (1990-09-01), Yamamoto et al.
patent: 6468558 (2002-10-01), Wong
patent: 2007/0166239 (2007-07-01), Lin
patent: 2007/0166800 (2007-07-01), Lin
patent: 1095951 (1994-12-01), None
patent: 93105862.7 (2000-09-01), None
patent: 0025766 (1981-03-01), None
patent: 0025766 (1981-03-01), None
patent: 2476488 (1981-08-01), None
patent: 57002220 (1982-01-01), None
patent: 01093540 (1989-04-01), None
patent: 1186818 (1989-07-01), None
patent: WO 2005/014038 (2005-02-01), None
US 6,008,200, 12/1999, Krieg et al. (withdrawn)
Lin et al. A new immunostimulatory complex PICKCa in experimental rabies: antiviral and adjvuant effects. Archives of Virology, vol. 131, Nos. 3-4, Sep. 1993, 307-319.
Morahan et al. Antiviral activity and side effects of polyriboinosinic-cytidylic acid complexes as affected by molecular size. Proc. Nat. Acad. Sci., USA, Apr. 1972, vol. 69, No. 4, 842-846.
Zong et al. Study on determining the molecular weight of PICKCa and PI,PC with the method of polyacrylamide gel electrophoresis. Chinese Journal of Pharmaceutical Analysis. 1993, vol. 13, No. 4, pp. 219-222.
Hu, Q.G. Basic Research on Poly I:C (review). Chinese Medical and Pharmaceutical Industry Journal. 1983, (9) 3134. (With English Abstract).
Hu, Q.G. Tianjin Poly I:C Laboratory Research and Clinical Application. Fujian Medical Journal. 1983, vol. 12, No. 6, pp. 31-34. (With English Abstract).
Zong, J., et al. Study on Determining the Molecular Weight of PICKCa and PI, PC with the Method of Polyacrylamide Gel Electrophoresis. Chinese Journal of Pharmaceutical Analysis. 1993, vol. 13, No. 4, pp. 219-222. (With English Abstract).
Houston et al. “Modified Polyriboinosinic-Polyribocytidylic Acid, an Immunological Adjuvant,” Infection and Immunity, American Society for Microbiology, Jul. 1976, vol. 14(1) p. 318-319.
Kende et al. “Enhanced Therapeutic Efficacy of Poly(ICLC) and Ribavirin Combinations against Rift Valley Fever Virus Infection in Mice,” Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Jul. 1987, vol. 31(7) p. 986-990.
Lake et al. Involvement of protein kinase C in macrophages activation by poly (C). American Journal of Physiology (1994) vol. 266(1) pp. C134-C142.
Levy et al. “Immune Modulating Effects of Poly ICLC,” Annals New York Academy of Sciences, 1980, p. 33-41.
Lin et al. A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects. Archives of Virology (1993) col. 131: pp. 307-319.
Ellouz, F., et al. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochemical and Biophysical Research Communications. 1974, vol. 59, No. 4, pp. 1317-1325.
Gupta, R. K., et al. Adjuvants for human vaccines—current status, problems and future prospects. Vaccine. 1995, vol. 13, No. 14, pp. 1263-1278.
Gupta, R. K., et al. Adjuvants—a balance between toxicity and adjuvanticity. Vaccine. 1993, vol. 11, pp. 293-306.
Kanzler, H., et al. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nature Medicine. 2007, vol. 13, No. 5, pp. 552-559. E-pub May 3, 2007.
Kenney, R. T., et al. Meeting report, 2nd meeting on novel adjuvants currently in/close to human clinical testing, World Health Organization—Organization Mondiale de la Sante, Fondation Merieux, Annecy, France, Jun. 5-7, 2000. Vaccine. 2002, vol. 20, pp. 2155-2163.
Morahan, P. S., et al. Antiviral activity and side effects of polyriboinosinic-cytidylic acid complexes as affected by molecular size. Proceedings of the National Academy of Sciences USA. 1972, vol. 69, No. 4, pp. 842-846.
Norlund, J. J., et al. Inhibition of biologic activity of Poly I: Poly C by human plasma (34492). Proc Soc Exp Biol Med. 1970, vol. 133, pp. 439-444.
Phillips, B. M., et al. Systemic toxicity of polyinosinic acid: polycytidylic acid in rodents and dogs. Toxicology and Applied Pharmacology. 1971, vol. 18, pp. 220-230.
Sela, M. Antigenicity: some molecular aspects. Science. 1969, vol. 166, pp. 1365-1374.
Stern, R. A nuclease from animal serum which hydrolyzes double-stranded RNA. Biochemical and Biophysical Research Communications. 1970, vol. 41, No. 3, pp. 608-614.
Wright, C. L., et al. The adjuvant effects mycoviral dsRNA and polyinosinic:polycytidylic acid on the murine immune response. Biochemical and Biophysical Research Communications. 1985, vol. 131, No. 2, pp. 949-955.
Lin; et al., “A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects”, Archives of Virology (1993), 131(3-4):307-19.
Lin; et al., “Experimental Study of Rabies Vaccine Plus Pika Adjuvant”, Chinese Journal of Biologicals (1998), 11(3):4 pages, Translated by Schreiber Translations, Inc. (2008).
Zong; et al., “Study on Determining the Molecular Weight of PICKCa and PI. PC with the Method of Polyacrylamide Gel Electrophoresis(PAGE)”, Chinese Journal of Pharmaceutical Analysis (1993), 13:s219-222, English translation.
Zong Jianchao et al.(1993) “Study on Determining the Molecular Weight of PICKCa and PI.PC with the Method of Polyacrylamide Gel Electrophoresis (PAGE)” Chinese Journal of Pharm. Analysis 13 (4): 219-222 (with English Translation).
Champney, et al., Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans, Infect Immun. Sep. 1979; 25(3): 831-837.
De Clercq, Degradation of Poly(inosinic acid) • poly(cytidylic acid) [(I)n• (Cn)] by Human Plasma, European Journal of Biochemistry, vol. 93 Issue 1, pp. 165-172, Jun. 28, 2008.
Gatmaitan, et al., Modified Polyriboinosiniic-Polyribocytidylic Acid Complex: Induction of Serum Interferon, Fever, and Hypotension in. Rabbits, Antimicrobial agents and chemotherapy, Jan. 1980, p. 49-54, vol. 17. No. 1.
Levy, et al., Interferon induction in primates by stabilized polyriboinosinic acid-polyribocytidylic acid: effect of component size, Infect Immun. Nov. 1981; 34(2): 416-421.
Machida, et al., Relationship between the molecular size of poly I-poly C and its biological activity, Jpn J Microbiol. Apr. 1976;20(2):71-76.
Shu, et al., Biological function and application of Poly I:C, the First Affiliated Hospital of Xian Medical College, Shanxi Journal of Medicine, 1989, 18(10), 40-42.
Smorodintsev, et al., Comparative study of the toxicity of poly G-poly C and poly I-poly C in different objects, Vopr Virusol. Mar.-Apr. 1978;(2):201-206.
Stringfellow, et
Bozicevic Field & Francis LLP
Francis Carol L.
Le Emily M.
Newbiomed Pika Pte Ltd
LandOfFree
Polyinosinic acid-polycytidylic acid-based adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyinosinic acid-polycytidylic acid-based adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyinosinic acid-polycytidylic acid-based adjuvant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4224434